| Literature DB >> 27993850 |
Michail S Lionakis1, Nathaniel D Albert2, Muthulekha Swamydas3, Chyi-Chia R Lee4, Pius Loetscher5, Dimitrios P Kontoyiannis6.
Abstract
Systemic candidiasis is a leading cause of nosocomial bloodstream infection with a high mortality rate despite treatment. Immune-based strategies are needed to improve outcomes. We previously reported that genetic deficiency in the chemokine receptor CCR1 improves survival and ameliorates tissue damage in Candida-infected mice. Here, we found that treatment of immunocompetent Candida-infected mice with the CCR1-selective antagonist BL5923 improves survival, decreases the kidney fungal burden, and protects from renal tissue injury.Entities:
Keywords: CCR1; Candida; candidiasis; chemokine receptor
Mesh:
Substances:
Year: 2017 PMID: 27993850 PMCID: PMC5328547 DOI: 10.1128/AAC.02365-16
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191